Effect sizes and test-retest reliability of the fMRI-based neurologic pain signature
Xiaochun Han,
Yoni K. Ashar,
Philip Kragel,
Bogdan Petre,
Victoria Schelkun,
Lauren Y. Atlas,
Luke J. Chang,
Marieke Jepma,
Leonie Koban,
Elizabeth A. Reynolds Losin,
Mathieu Roy,
Choong-Wan Woo,
Tor D. Wager
Affiliations
Xiaochun Han
Faculty of Psychology, Beijing Normal University, Beijing, China; Dartmouth College, Hanover, NH, United States
Yoni K. Ashar
Weill Cornell Medical College, New York, NY, United States
Philip Kragel
Emory University, Atlanta, GA, United States
Bogdan Petre
Dartmouth College, Hanover, NH, United States
Victoria Schelkun
Columbia University, New York, NY, United States
Lauren Y. Atlas
National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, MD, United States; National Institute of Mental Health, National Institutes of Health, Bethesda, MD, United States; National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, United States
Luke J. Chang
Dartmouth College, Hanover, NH, United States
Marieke Jepma
University of Amsterdam, Amsterdam, Netherlands
Leonie Koban
INSEAD Fontainebleau & ICM paris, Paris, France
Elizabeth A. Reynolds Losin
Department of Psychology, University of Miami, Miami FL, United States
Mathieu Roy
Department of Psychology, McGill University, Montreal, Quebec, Canada
Choong-Wan Woo
Center for Neuroscience Imaging Research, Institute for Basic Science, Suwon, Gyeonggi-do, South Korea
Identifying biomarkers that predict mental states with large effect sizes and high test-retest reliability is a growing priority for fMRI research. We examined a well-established multivariate brain measure that tracks pain induced by nociceptive input, the Neurologic Pain Signature (NPS). In N = 295 participants across eight studies, NPS responses showed a very large effect size in predicting within-person single-trial pain reports (d = 1.45) and medium effect size in predicting individual differences in pain reports (d = 0.49). The NPS showed excellent short-term (within-day) test-retest reliability (ICC = 0.84, with average 69.5 trials/person). Reliability scaled with the number of trials within-person, with ≥60 trials required for excellent test-retest reliability. Reliability was tested in two additional studies across 5-day (N = 29, ICC = 0.74, 30 trials/person) and 1-month (N = 40, ICC = 0.46, 5 trials/person) test-retest intervals. The combination of strong within-person correlations and only modest between-person correlations between the NPS and pain reports indicate that the two measures have different sources of between-person variance. The NPS is not a surrogate for individual differences in pain reports but can serve as a reliable measure of pain-related physiology and mechanistic target for interventions.